A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF SONROTOCLAX (BGB-11417) PLUS ZANUBRUTINIB (BGB-3111) COMPARED WITH VENETOCLAX PLUS ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA

Registry ID

BGB-11417-304

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BEONE MEDICINES LTD.

Last update

2025-11-25

Conditions

• LYMPHOCYTIC LEUKEMIA

Related clinical trials

• A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314)

View on source registry